Atlas Venture is a biotech-focused, early-stage venture capital firm that creates and invests in life sciences startup companies in the USA. Atlas is based in Cambridge, Massachusetts. Since 1993, Atlas has invested in over 150 early stage life sciences companies.

Founded in 2005, Clarus is an experienced team of healthcare investors with deep scientific and clinical development expertise. In an ever-changing investment landscape, we strive to generate outstanding returns for our investors and thrive on discovering and developing products that improve people’s lives. Clarus manages $1.7B across three funds and invests through multiple platforms including risk-sharing partnerships, pre-commercial royalties, and traditional venture investments. Our venture strategy focuses on investing in innovative therapeutics at all stages of development, in both private and public companies. The Clarus team has collectively led over 120 healthcare investments.
SV Life Sciences (SVLS) is a leading, international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the Firm closed its first dedicated life sciences fund in 1994. SVLS' team of 35 professionals is organized according to experience and specialization into three practice areas: Biotechnology, Medical Devices, and Healthcare Services/Health IT. These individuals' diverse and complementary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds. SVLS has offices in Boston, London and San Francisco.

Lund University, the Division of Molecular Medicine and Gene Therapy is located in the Biomedical Center in Lund, Sweden. Established as a joint venture between the Medical Faculty at Lund University and the Hematology Clinic at Lund University Hospital has their mission to translate basic science to clinical applications. The Division of Molecular Hematology aims to generate new knowledge about the regulation of blood cell development by applying recent advances in stem cell technology, in order to dissect the molecular regulation of hematopoiesis. Their mission is to translate this information into clinical contexts to advance the full potential of cell and gene therapies deploying hematopoetic stem cells.

The University Health Network (UHN) is made up of Princess Margaret Cancer Center, Toronto General Hospital, Toronto Rehabilitation Institute, and Toronto Western Hospital. UHN is one of Canada’s largest teaching hospitals.

Centre for Commercialisation of Regenerative Medicine

The Centre for Commercialization of Regenerative Medicine (CCRM) is a not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell and biomaterial-based therapies